University of North Carolina at Chapel Hill research set the stage to seek emergency authorization of the first oral antiviral drug to treat COVID-19, a pill developed by the pharmaceutical companies Merck and Ridgeback Biotherapeutics. William Fischer, MD, at the 黑料网 led pivotal clinical trials on the drug molnupiravir.
Scientists at the University of North Carolina at Chapel Hill say a twice-daily pill 鈥� molnupiravir 鈥� could change the way COVID-19 is treated. Today鈥檚 announcement by Merck Co. to seek emergency authorization by the Food and Drug Administration reflects early research and testing conducted at the 黑料网-Chapel Hill.听
听showed the experimental COVID-19 pill听reduced hospitalizations and deaths by half in people recently infected with coronavirus.听黑料网-Chapel Hill began working on听molnupiravir听in听2016听and听showed the drug could be a weapon against coronaviruses and future pandemics.听听
鈥淭his is a听real听game changer听for听a听pandemic like COVID-19 because it allows听us to treat people quicker听with a method听that鈥檚 convenient and accessible,鈥澨齭aid听William A. Fischer II, an associate professor鈥痮f pulmonology and critical care at the听黑料网听and听director of emerging pathogens at the听.听
Read more from the .